A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
At a glance
- Drugs Bimekizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors UCB Biopharma
- 05 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2017 This trial has been discontinued in Germany.
- 21 Nov 2016 New trial record